RARE DISEASE LINKED TO MS DRUG WORRIES FDA

The risk of a rare brain disease and other infections remains the primary concern of federal regulators as they seek independent advice on whether to allow a promising multiple sclerosis drug back on the market, according to documents released Monday. If Tysabri (pronounced ty-SAH-bree) returns to the market, its use should be restricted and monitored to curtail the risk patients run of developing progressive multifocal leukoencephalopathy, or PML, and other opportunistic infections, according to Food and Drug Administration officials.

WJLA.com (http://www.wjla.com/news/stories/0306/308296.html)